US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Jyong Biotech

2.37

+0.07003.04%

Post-market: 2.33-0.0400-1.69%19:01 EDT

Volume:21.74K

Turnover:51.62K

Market Cap:180.19M

PE:-37.05

High:2.42

Open:2.30

Low:2.30

Close:2.30

52wk High:67.00

52wk Low:1.43

Shares:76.03M

Float Shares:28.74M

Volume Ratio:1.09

T/O Rate:0.08%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.0640

EPS(LYR):-0.0640

ROE:--

ROA:-12.01%

PB:-7.23

PE(LYR):-37.05

Loading ...

Overview Company News Filings

Jyong Biotech CEO targets 2029-2030 FDA NDA filing for Botreso, PharmaBoardroom interview says

Jyong Biotech FY25 net loss widens 55% to US$4.67 million

Jyong Biotech delays annual Form 20-F filing, cites audit completion needs

Jyong Biotech files Form 3; CFO Zhang Wei reports no beneficial ownership

Jyong Biotech files Form 3 showing CEO Fu-Feng Kuo as 10% owner

Jyong Biotech director Chi Pang-Chieh files initial beneficial ownership statement

Jyong Biotech updates MCS-2 BPH/LUTS program; Phase III trials span 27 U.S. centers in 19 states

Jyong Biotech Reports Positive Phase II Results for MCS-8 in Prostate Cancer Prevention and Metabolic Health

Jyong Biotech Ltd: Wei (Vivi) Zhang Has Been Appointed as Company’s CFO

THOMSON REUTERS

Jyong Biotech Ltd: Zhang Will Be Replacing Alfred Ying

THOMSON REUTERS

Jyong Biotech Ltd. Appoints Wei Zhang as Chief Financial Officer

BUZZ-U.S. STOCKS ON THE MOVE-ResMed, Stryker, ALX Oncology

BUZZ-Jyong Biotech rises on prostate cancer drug mid‑stage trial data

Jyong Biotech Reports Phase II Trial Results Showing MCS-8 Lowers Cholesterol and May Prevent Prostate Cancer

Jyong Biotech Ltd - Mcs-8 Shows Potential in Alleviating High-Grade Malignancy Risk

THOMSON REUTERS

Jyong Biotech Ltd - Mcs-8 Shows 27.3% Reduction in Prostate Cancer Incidence

THOMSON REUTERS

Jyong Biotech Ltd - Phase Ii Trial Shows Significant Cholesterol Reduction With Mcs-8

THOMSON REUTERS

Jyong Biotech Subsidiary Announces Phase Ii Clinical Data on Cholesterol and Ldh Indicators for Mcs-8 (Pcp), Indicating Potential in Prostate Cancer Prevention and Metabolic Value

THOMSON REUTERS

After the recent decline, Jyong Biotech Ltd. (NASDAQ:MENS) CEO Fu-Feng Kuo's holdings have lost 33% of their value

Simply Wall St.

NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:39 AM

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigeractivity.com/stock/MENS/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"MENS","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MENS\",,,,,undefined,":{"symbol":"MENS","market":"US","secType":"STK","nameCN":"Jyong Biotech","latestPrice":2.37,"timestamp":1787947200000,"preClose":2.3,"halted":0,"volume":21737,"hourTrading":{"tag":"盘后","latestPrice":2.33,"preClose":2.37,"latestTime":"19:01 EDT","volume":1182,"amount":2768.46,"timestamp":1787958070409,"change":-0.04,"changeRate":-0.016878,"amplitude":0.016878},"delay":0,"changeRate":0.03043478260869578,"floatShares":28737800,"shares":76027667,"eps":-0.063976,"marketStatus":"Market Closed","change":0.07,"latestTime":"08-28 16:00:00 EDT","open":2.3,"high":2.42,"low":2.3,"amount":51620,"amplitude":0.052174,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.063976,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1788163200000},"marketStatusCode":7,"adr":0,"listingDate":1744862400000,"exchange":"NASDAQ","adjPreClose":2.3,"preHourTrading":{"tag":"盘前","latestPrice":2.3,"preClose":2.3,"latestTime":"07:10 EDT","volume":26,"amount":59.8,"timestamp":1787915433193,"change":0,"changeRate":0,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":2.33,"preClose":2.37,"latestTime":"19:01 EDT","volume":1182,"amount":2768.46,"timestamp":1787958070409,"change":-0.04,"changeRate":-0.016878,"amplitude":0.016878},"volumeRatio":1.091304127547697,"impliedVol":1.6726,"impliedVolPercentile":0.6184},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MENS\",,,,,undefined,":{"symbol":"MENS","floatShares":28737800,"roa":"-12.01%","roe":"--","lyrEps":-0.063976,"volumeRatio":1.091304127547697,"shares":76027667,"dividePrice":0,"high":2.42,"amplitude":0.052174,"preClose":2.3,"low":2.3,"week52Low":1.43,"pbRate":"-7.23","week52High":67,"institutionHeld":0,"latestPrice":2.37,"eps":-0.063976,"divideRate":0,"volume":21737,"delay":0,"ttmEps":-0.063976,"open":2.3,"prevYearClose":3.95,"prevWeekClose":2.18,"prevMonthClose":2.15,"prevQuarterClose":2.07,"fiveDayClose":2.18,"twentyDayClose":2.15,"sixtyDayClose":2.09},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MENS\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-05-14","symbol":"MENS","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1778731200000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2026-01-09","symbol":"MENS","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1767934800000,"reportTimeType":"post","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MENS\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"MENS\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/MENS\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"MENS","date":"2026-08-28","current":-37.045142,"percent":0.786667,"low":-1671.474987,"twenty":-1003.088768,"median":-79.119603,"eighty":-35.916828,"high":-24.792147,"avg":-414.55964,"sd":517.469127,"marketCap":170736840},"quantilePoints":[{"date":"2025-06-20","current":-203.776286,"twenty":-230.665817,"median":-203.776286,"eighty":-192.159849,"marketCap":615200608},{"date":"2025-06-27","current":-224.00343,"twenty":-215.938323,"median":-202.579037,"eighty":-189.726725,"marketCap":676266355},{"date":"2025-07-03","current":-195.234603,"twenty":-221.003604,"median":-203.808474,"eighty":-195.578845,"marketCap":589413267},{"date":"2025-07-11","current":-224.00343,"twenty":-224.00343,"median":-203.776286,"eighty":-193.660924,"marketCap":676266355},{"date":"2025-07-18","current":-270.722038,"twenty":-248.100396,"median":-208.75841,"eighty":-195.234603,"marketCap":817309833},{"date":"2025-07-25","current":-289.655369,"twenty":-270.672861,"median":-224.00343,"eighty":-195.578845,"marketCap":874469558},{"date":"2025-08-01","current":-468.661403,"twenty":-288.081689,"median":-239.863168,"eighty":-197.84101,"marketCap":1414888775},{"date":"2025-08-08","current":-841.426716,"twenty":-379.453451,"median":-248.592171,"eighty":-201.860688,"marketCap":2540267255},{"date":"2025-08-15","current":-973.468255,"twenty":-555.508836,"median":-270.599094,"eighty":-203.789161,"marketCap":2938900662},{"date":"2025-08-22","current":-1061.25006,"twenty":-894.144977,"median":-285.475283,"eighty":-204.775034,"marketCap":3203913932},{"date":"2025-08-29","current":-1365.166899,"twenty":-1022.00643,"median":-288.917707,"eighty":-208.610878,"marketCap":4121438867},{"date":"2025-09-05","current":-1355.085515,"twenty":-1114.607628,"median":-347.684797,"eighty":-209.004298,"marketCap":4091003169},{"date":"2025-09-12","current":-1584.006693,"twenty":-1218.618003,"median":-441.613788,"eighty":-224.00343,"marketCap":4782116207},{"date":"2025-09-19","current":-1318.177851,"twenty":-1286.23704,"median":-523.494295,"eighty":-224.00343,"marketCap":3979578933},{"date":"2025-09-26","current":-1509.21812,"twenty":-1347.708893,"median":-786.347936,"eighty":-227.445854,"marketCap":4556329503},{"date":"2025-10-03","current":-1324.54586,"twenty":-1347.708893,"median":-940.396399,"eighty":-233.593039,"marketCap":3998803952},{"date":"2025-10-10","current":-1377.018254,"twenty":-1355.085515,"median":-1003.088768,"eighty":-246.133297,"marketCap":4157218108},{"date":"2025-10-17","current":-1489.859372,"twenty":-1369.101097,"median":-1041.824955,"eighty":-247.362734,"marketCap":4497885445},{"date":"2025-10-24","current":-1542.331766,"twenty":-1407.075256,"median":-1114.607628,"eighty":-248.592171,"marketCap":4656299601},{"date":"2025-10-31","current":-1146.49633,"twenty":-1407.075256,"median":-1138.789207,"eighty":-259.411217,"marketCap":3461272420},{"date":"2025-11-07","current":-953.163578,"twenty":-1404.508884,"median":-1114.607628,"eighty":-270.476151,"marketCap":2877600843},{"date":"2025-11-14","current":-974.050648,"twenty":-1403.763891,"median":-1074.835074,"eighty":-270.722038,"marketCap":2940658906},{"date":"2025-11-21","current":-835.482773,"twenty":-1377.018254,"median":-1042.570424,"eighty":-274.164462,"marketCap":2522322492},{"date":"2025-11-28","current":-692.839373,"twenty":-1370.684528,"median":-1023.721118,"eighty":-283.213119,"marketCap":2091682067},{"date":"2025-12-05","current":-743.528724,"twenty":-1368.302652,"median":-1011.760759,"eighty":-287.245672,"marketCap":2244713218},{"date":"2025-12-12","current":-678.575033,"twenty":-1365.754127,"median":-990.09803,"eighty":-288.081689,"marketCap":2048618024},{"date":"2025-12-19","current":-84.821879,"twenty":-1357.495212,"median":-973.759452,"eighty":-287.245672,"marketCap":256077253},{"date":"2025-12-26","current":-90.680447,"twenty":-1355.282225,"median":-962.970312,"eighty":-270.623683,"marketCap":273764270},{"date":"2026-01-02","current":-100.614541,"twenty":-1352.134866,"median":-921.074128,"eighty":-247.854509,"marketCap":303755300},{"date":"2026-01-09","current":-101.888143,"twenty":-1343.873049,"median":-841.426716,"eighty":-225.3804,"marketCap":307600304},{"date":"2026-01-16","current":-90.347797,"twenty":-1334.971925,"median":-784.679158,"eighty":-205.709406,"marketCap":266074262},{"date":"2026-01-23","current":-82.514173,"twenty":-1329.160825,"median":-777.915972,"eighty":-197.84101,"marketCap":243004240},{"date":"2026-01-30","current":-66.846925,"twenty":-1324.749636,"median":-757.793064,"eighty":-192.283954,"marketCap":196864194},{"date":"2026-02-06","current":-43.346053,"twenty":-1323.272258,"median":-744.420245,"eighty":-110.344859,"marketCap":127654126},{"date":"2026-02-13","current":-38.384758,"twenty":-1315.070263,"median":-743.019283,"eighty":-99.712528,"marketCap":113043111},{"date":"2026-02-20","current":-51.963039,"twenty":-1302.639909,"median":-725.95302,"eighty":-91.39228,"marketCap":153031151},{"date":"2026-02-27","current":-60.057784,"twenty":-1286.23704,"median":-692.839373,"eighty":-89.564435,"marketCap":176870174},{"date":"2026-03-06","current":-57.446576,"twenty":-1274.188557,"median":-672.461744,"eighty":-85.125381,"marketCap":169180167},{"date":"2026-03-13","current":-56.140972,"twenty":-1274.111229,"median":-573.585372,"eighty":-82.019955,"marketCap":165335163},{"date":"2026-03-20","current":-46.740623,"twenty":-1273.601789,"median":-468.661403,"eighty":-78.07512,"marketCap":137651136},{"date":"2026-03-27","current":-52.746402,"twenty":-1273.601789,"median":-388.787461,"eighty":-70.812259,"marketCap":155338153},{"date":"2026-04-02","current":-59.535543,"twenty":-1261.875188,"median":-347.684797,"eighty":-63.609027,"marketCap":175332173},{"date":"2026-04-10","current":-69.980375,"twenty":-1239.272545,"median":-288.180044,"eighty":-63.922372,"marketCap":206092203},{"date":"2026-04-17","current":-67.630287,"twenty":-1224.997133,"median":-279.819872,"eighty":-64.39239,"marketCap":199171196},{"date":"2026-04-24","current":-59.274422,"twenty":-1219.804849,"median":-270.476151,"eighty":-63.086786,"marketCap":174563172},{"date":"2026-05-01","current":-59.274422,"twenty":-1218.712729,"median":-247.977452,"eighty":-60.266681,"marketCap":174563172},{"date":"2026-05-08","current":-53.529764,"twenty":-1181.046406,"median":-233.593039,"eighty":-59.483319,"marketCap":157645155},{"date":"2026-05-15","current":-54.313127,"twenty":-1158.867362,"median":-224.00343,"eighty":-58.073266,"marketCap":159952158},{"date":"2026-05-22","current":-34.243665,"twenty":-1148.331229,"median":-208.512523,"eighty":-57.133231,"marketCap":159952158},{"date":"2026-05-29","current":-35.757904,"twenty":-1142.675525,"median":-203.776286,"eighty":-56.297645,"marketCap":167025170},{"date":"2026-06-05","current":-33.374044,"twenty":-1134.700579,"median":-196.095209,"eighty":-56.036524,"marketCap":155890158},{"date":"2026-06-12","current":-27.096545,"twenty":-1121.197411,"median":-193.267504,"eighty":-54.992041,"marketCap":126567962},{"date":"2026-06-18","current":-25.427843,"twenty":-1108.804685,"median":-184.907332,"eighty":-54.417575,"marketCap":118773454},{"date":"2026-06-26","current":-30.195563,"twenty":-1095.428198,"median":-114.624161,"eighty":-53.529764,"marketCap":141043477},{"date":"2026-07-02","current":-32.579424,"twenty":-1082.986082,"median":-103.543825,"eighty":-52.746402,"marketCap":152178488},{"date":"2026-07-10","current":-36.552524,"twenty":-1060.672665,"median":-99.487025,"eighty":-51.754143,"marketCap":170736840},{"date":"2026-07-17","current":-36.552524,"twenty":-1055.204554,"median":-92.175643,"eighty":-49.821849,"marketCap":170736840},{"date":"2026-07-24","current":-43.068409,"twenty":-1041.194934,"median":-90.680447,"eighty":-46.740623,"marketCap":201172538},{"date":"2026-07-31","current":-35.440056,"twenty":-1035.692974,"median":-89.564435,"eighty":-44.129415,"marketCap":165540502},{"date":"2026-08-07","current":-32.102652,"twenty":-1023.721118,"median":-86.906434,"eighty":-41.955941,"marketCap":149951486},{"date":"2026-08-14","current":-32.738348,"twenty":-1022.39985,"median":-84.821879,"eighty":-38.384758,"marketCap":152920822},{"date":"2026-08-21","current":-34.327588,"twenty":-1020.43275,"median":-82.267064,"eighty":-36.552524,"marketCap":160344163},{"date":"2026-08-28","current":-36.552524,"twenty":-1003.088768,"median":-79.119603,"eighty":-35.916828,"marketCap":170736840}],"updateTime":1788146500513},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MENS\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2639788622","title":"Jyong Biotech CEO targets 2029-2030 FDA NDA filing for Botreso, PharmaBoardroom interview says","url":"https://stock-news.laohu8.com/highlight/detail?id=2639788622","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639788622?lang=en_us&edition=fundamental","pubTime":"2026-05-29 20:05","pubTimestamp":1780056341,"startTime":"0","endTime":"0","summary":"Jyong Biotech CEO Fu-Feng Kuo outlined an FDA plan for Botreso, its lead botanical drug candidate for benign prostatic hyperplasia.Targeted combined NDA submission in 2029-2030, contingent on a US pharmacokinetic comparability study for API-1 versus API-2.Planned Phase III trial using API-2 to support supply-chain requirements for FDA review.Two pivotal studies, two one-year open-label extensions in the US and Taiwan cited as showing no emergent safety signals.US commercialization prioritized first, positioning FDA approval as a gateway for Brazil, Israel, and broader Asia.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260529:nNDL3498Xk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014021.USD","IE00BN0W2T93.GBP","LU2210150020.SGD","IE00BKPKM429.USD","SG9999014039.USD","BK4588","SG9999014013.SGD","BK4112","LU2095319765.USD","SG9999014005.SGD","NDAQ","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","MENS","LU0314104364.USD","IE00BN0W2V16.EUR","BK4585","IE00BGHQF748.EUR","IE00BN0W2W23.USD","LU2210149790.SGD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635835760","title":"Jyong Biotech FY25 net loss widens 55% to US$4.67 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2635835760","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635835760?lang=en_us&edition=fundamental","pubTime":"2026-05-15 18:19","pubTimestamp":1778840392,"startTime":"0","endTime":"0","summary":"Jyong Biotech posted a net loss of US $4.67 million, widening from US $3.02 million a year earlier.Operating loss widened to US $2.61 million as total operating expenses rose 27% to US $2.61 million.General and administrative costs climbed 61% to US $1.75 million, while research and development expense fell 12% to US $813,000.Interest expense more than doubled to US $2.54 million, while interest income rose to US $610,000 from US $7,000.Botreso API-2 CMC package was initially submitted to the U.S. FDA in October 2024, with updated Module 3 and stability data slated for submission in Q2 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jyong Biotech Ltd. published the original content used to generate this news brief via EDGAR, the E","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nNDL7R481W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MENS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631544178","title":"Jyong Biotech delays annual Form 20-F filing, cites audit completion needs","url":"https://stock-news.laohu8.com/highlight/detail?id=2631544178","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631544178?lang=en_us&edition=fundamental","pubTime":"2026-04-30 01:12","pubTimestamp":1777482754,"startTime":"0","endTime":"0","summary":"Jyong Biotech filed a Form 12b-25 to notify investors it will miss deadline for its annual Form 20-F for fiscal year ended Dec. 31, 2025.Delay was attributed to additional time needed to finalize audited financial statements and related disclosures.Company expects to file Form 20-F on or before 15th calendar day following prescribed due date.Management indicated it does not expect a significant change in results of operations versus corresponding prior-year period.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jyong Biotech Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 29, 2","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260429:nNDL11cggC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MENS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627440097","title":"Jyong Biotech files Form 3; CFO Zhang Wei reports no beneficial ownership","url":"https://stock-news.laohu8.com/highlight/detail?id=2627440097","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627440097?lang=en_us&edition=fundamental","pubTime":"2026-04-14 23:46","pubTimestamp":1776181616,"startTime":"0","endTime":"0","summary":"Jyong Biotech CFO Wei  Zhang filed an initial Form 3 insider ownership statement dated April 13, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jyong Biotech Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 14, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260414:nNDLc0PtG8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MENS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625947189","title":"Jyong Biotech files Form 3 showing CEO Fu-Feng Kuo as 10% owner","url":"https://stock-news.laohu8.com/highlight/detail?id=2625947189","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625947189?lang=en_us&edition=fundamental","pubTime":"2026-04-08 22:12","pubTimestamp":1775657521,"startTime":"0","endTime":"0","summary":"Jyong Biotech CEO Fu-Feng Kuo filed an initial Form 3 as director, 10% owner.Kuo reported indirect ownership of 25,349,500 common shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jyong Biotech Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 08, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260408:nNDLbDxSX2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MENS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624468595","title":"Jyong Biotech director Chi Pang-Chieh files initial beneficial ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2624468595","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624468595?lang=en_us&edition=fundamental","pubTime":"2026-04-02 02:57","pubTimestamp":1775069828,"startTime":"0","endTime":"0","summary":"Jyong Biotech filed an initial Form 3 naming Chi Pang-Chieh as a director on 04/01/2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jyong Biotech Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 01, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260401:nNDL134G6S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MENS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622782971","title":"Jyong Biotech updates MCS-2 BPH/LUTS program; Phase III trials span 27 U.S. centers in 19 states","url":"https://stock-news.laohu8.com/highlight/detail?id=2622782971","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622782971?lang=en_us&edition=fundamental","pubTime":"2026-03-27 20:30","pubTimestamp":1774614624,"startTime":"0","endTime":"0","summary":"Jyong Biotech reported updated information on MCS-2, an investigational oral botanical drug candidate being studied for benign prostatic hyperplasia/lower urinary tract symptoms.The company said MCS-2 has completed four Phase III clinical trials in the U.S. and Taiwan, including two pivotal trials and two open-label extension studies.Jyong Biotech stated that the Phase III clinical trial report was completed in 2017, and the drug has not been approved for commercial use in any jurisdiction.The company reported that U.S. trials were conducted at 27 centers in 19 states, and Taiwan trials were conducted at 12 hospitals.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260327:nNDL6KCYYX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014013.SGD","LU2210149790.SGD","IE00BKPKM429.USD","IE00BN0W2W23.USD","IE00BGHQF748.EUR","BK4112","LU2095319765.USD","BK4139","BK4585","NDAQ","LU2210150020.SGD","SG9999014021.USD","LU0314104364.USD","SG9999014005.SGD","IE00B64PRP62.GBP","BK4588","IE00B3QW5Z07.USD","IE00BN0W2V16.EUR","SG9999014039.USD","IE00BN0W2T93.GBP","MENS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2610921957","title":"Jyong Biotech Reports Positive Phase II Results for MCS-8 in Prostate Cancer Prevention and Metabolic Health","url":"https://stock-news.laohu8.com/highlight/detail?id=2610921957","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610921957?lang=en_us&edition=fundamental","pubTime":"2026-02-12 21:30","pubTimestamp":1770903036,"startTime":"0","endTime":"0","summary":"Jyong Biotech Ltd. announced the successful completion of a Phase II clinical trial for its lead investigational candidate, MCS-8. The company reported that the trial demonstrated positive outcomes in both oncological and metabolic health endpoints, specifically addressing prostate cancer risk and improvements in lipid profiles among the aging male population. The results of the Phase II study have already been presented. MCS-8, along with another candidate, MCS-2, remains under investigational status and has not received regulatory approval for commercial use in any jurisdiction. Jyong Biotech has also entered into non-binding agreements with pharmaceutical partners in South Korea and Vietnam to explore future commercialization opportunities for its pipeline products.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purpo","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260212:nNDL8lS6Yk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","LU2210149790.SGD","NDAQ","IE00B64PRP62.GBP","IE00BGHQF748.EUR","SG9999014021.USD","IE00B3QW5Z07.USD","SG9999014005.SGD","BK4585","LU2095319765.USD","LU0314104364.USD","LU2210150020.SGD","SG9999014013.SGD","MENS","BK4139","BK4588","SG9999014039.USD","BK4112"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2609511273","title":"Jyong Biotech Ltd: Wei (Vivi) Zhang Has Been Appointed as Company’s CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=2609511273","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609511273?lang=en_us&edition=fundamental","pubTime":"2026-02-07 05:33","pubTimestamp":1770413582,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260206:nFWN3Z21A7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MENS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2609511227","title":"Jyong Biotech Ltd: Zhang Will Be Replacing Alfred Ying","url":"https://stock-news.laohu8.com/highlight/detail?id=2609511227","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609511227?lang=en_us&edition=fundamental","pubTime":"2026-02-07 05:33","pubTimestamp":1770413582,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260206:nFWN3Z21A7:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MENS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2609212511","title":"Jyong Biotech Ltd. Appoints Wei Zhang as Chief Financial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2609212511","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609212511?lang=en_us&edition=fundamental","pubTime":"2026-02-07 05:31","pubTimestamp":1770413511,"startTime":"0","endTime":"0","summary":"Jyong Biotech Ltd. has appointed Wei  Zhang as its new Chief Financial Officer, effective February 6, 2026. Zhang replaces Alfred Ying in the role. She brings extensive experience in finance, having previously served as CFO and director at Global Mofy AI Limited and as a consultant for a private company’s initial public offering.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jyong Biotech Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 06, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260206:nNDL3Q3kzG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MENS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2607049612","title":"BUZZ-U.S. STOCKS ON THE MOVE-ResMed, Stryker, ALX Oncology","url":"https://stock-news.laohu8.com/highlight/detail?id=2607049612","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607049612?lang=en_us&edition=fundamental","pubTime":"2026-01-30 22:12","pubTimestamp":1769782350,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-ResMed, Stryker, ALX OncologyEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter: http","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260130:nL6N3YV0MZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DECK","SYK","ALXO","LXRX","LU0070217475.USD","BK4581","LU0683600562.USD","RMD","LU0345780521.USD","BK4146","DVN","SNDR","AXP","LU2242646821.SGD","PCVX","BK4534","CDE","IE000M9KFDE8.USD","CVX","AU","VZ","LU1150488135.SGD","XOM","LU2404859741.USD","SG9999002521.SGD","IE00BGHQF524.EUR","APA","ALV","LU0266512473.USD","IE00B2Q91V27.USD","LU0498741890.SGD","IE00BFXG1179.USD","LU2347655156.SGD","BK4532","CORT","LU0690374961.EUR","HL","LU2404859667.USD","MENS","BK4232","VEON","LU0690374615.EUR","TNXP","LU0234572021.USD","LU0170899867.USD","APD","IE00BWXC8680.SGD","KYIV","NEM"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2607344046","title":"BUZZ-Jyong Biotech rises on prostate cancer drug mid‑stage trial data","url":"https://stock-news.laohu8.com/highlight/detail?id=2607344046","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607344046?lang=en_us&edition=fundamental","pubTime":"2026-01-30 21:43","pubTimestamp":1769780637,"startTime":"0","endTime":"0","summary":"BUZZ-Jyong Biotech rises on prostate cancer drug midstage trial data** Shares of drugmaker Jyong Biotech MENS.O rise 2.68% to $2.63 premarket** Co says its experimental drug, MCS8, helped reduce risk of prostate cancer — a disease caused by abnormal cell growth in the prostate gland** Co says men on MCS8 had a 27% lower chance of developing prostate cancer vs placebo in a midstage trial** Trial also showed potential benefit for cholesterol control, with patients seeing lower total cholesterol, per co** Co says no serious side effects reported; longterm use did not affect liver, kidney or blood pressure** MENS is considering expanding use of MCS8 for high cholesterol and heart disease, co says** Shares up ~43% in 2025  ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260130:nL4N3YV1G0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MENS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2607454045","title":"Jyong Biotech Reports Phase II Trial Results Showing MCS-8 Lowers Cholesterol and May Prevent Prostate Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2607454045","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607454045?lang=en_us&edition=fundamental","pubTime":"2026-01-30 21:30","pubTimestamp":1769779854,"startTime":"0","endTime":"0","summary":"Jyong Biotech Ltd. has announced updated statistical analyses from its Phase II clinical trial of MCS-8 , an investigational plant-derived drug candidate, conducted in Taiwan. The results, which have already been presented, indicate that after two years of treatment, subjects receiving MCS-8 showed a statistically significant reduction in total cholesterol levels compared to baseline . Additionally, while a statistically significant increase in serum lactate dehydrogenase  levels was observed in the placebo group , no such increase occurred in the MCS-8 group. Based on these findings, Jyong Biotech is evaluating the feasibility of expanding MCS-8's indications to include lipid management, atherosclerosis, and cardiovascular diseases. MCS-8 remains an investigational drug and has not been approved for commercial use in any jurisdiction.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and time","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260130:nNDL3DJp5G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4112","LU2210150020.SGD","SG9999014005.SGD","SG9999014013.SGD","IE00BKPKM429.USD","LU0314104364.USD","SG9999014021.USD","IE00B3QW5Z07.USD","LU2095319765.USD","MENS","BK4139","NDAQ","IE00BGHQF748.EUR","BK4588","LU2210149790.SGD","SG9999014039.USD","IE00B64PRP62.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2607904514","title":"Jyong Biotech Ltd - Mcs-8 Shows Potential in Alleviating High-Grade Malignancy Risk","url":"https://stock-news.laohu8.com/highlight/detail?id=2607904514","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607904514?lang=en_us&edition=fundamental","pubTime":"2026-01-30 21:30","pubTimestamp":1769779800,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260130:nTUA1NBYB4:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MENS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2607504517","title":"Jyong Biotech Ltd - Mcs-8 Shows 27.3% Reduction in Prostate Cancer Incidence","url":"https://stock-news.laohu8.com/highlight/detail?id=2607504517","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607504517?lang=en_us&edition=fundamental","pubTime":"2026-01-30 21:30","pubTimestamp":1769779800,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260130:nTUA1NBYB4:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MENS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2607045174","title":"Jyong Biotech Ltd - Phase Ii Trial Shows Significant Cholesterol Reduction With Mcs-8","url":"https://stock-news.laohu8.com/highlight/detail?id=2607045174","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607045174?lang=en_us&edition=fundamental","pubTime":"2026-01-30 21:30","pubTimestamp":1769779800,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260130:nTUA1NBYB4:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MENS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2607045106","title":"Jyong Biotech Subsidiary Announces Phase Ii Clinical Data on Cholesterol and Ldh Indicators for Mcs-8 (Pcp), Indicating Potential in Prostate Cancer Prevention and Metabolic Value","url":"https://stock-news.laohu8.com/highlight/detail?id=2607045106","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607045106?lang=en_us&edition=fundamental","pubTime":"2026-01-30 21:30","pubTimestamp":1769779800,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260130:nTUA1NBYB4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MENS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2595739955","title":"After the recent decline, Jyong Biotech Ltd. (NASDAQ:MENS) CEO Fu-Feng Kuo's holdings have lost 33% of their value","url":"https://stock-news.laohu8.com/highlight/detail?id=2595739955","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595739955?lang=en_us&edition=fundamental","pubTime":"2025-12-29 18:34","pubTimestamp":1767004440,"startTime":"0","endTime":"0","summary":"Key Insights Insiders appear to have a vested interest in Jyong Biotech's growth, as seen by their sizeable ownership...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mens/jyong-biotech/news/after-the-recent-decline-jyong-biotech-ltd-nasdaqmens-ceo-fu","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mens/jyong-biotech/news/after-the-recent-decline-jyong-biotech-ltd-nasdaqmens-ceo-fu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["TQQQ","JYB","MNQmain","QLD","TSYW.SI",".IXIC","USAW.SI","QID","USJW.SI","PSQ","SQQQ","BK4139","NQmain","NVIW.SI","MENS"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2593435883","title":"NASDAQ TRADE HALT  VOLATILITY TRADING PAUSE AT 09:39 AM","url":"https://stock-news.laohu8.com/highlight/detail?id=2593435883","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593435883?lang=en_us&edition=fundamental","pubTime":"2025-12-22 22:39","pubTimestamp":1766414359,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALT  VOLATILITY TRADING PAUSE AT 09:39 AM","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251222:nAQN2LEQI6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MENS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":27,"code":"91000000","status":"200"}]}}